| Literature DB >> 25348652 |
Heiko Nathues, Johanna Meyer-Hamme, Petra Maass, Ruediger Goessl, Wibke Stansen, Rolf Steens, Elisabeth Grosse Beilage.
Abstract
BACKGROUND: The aim of the present study was to evaluate the feasibility of using a telephone survey in gaining an understanding of the possible herd and management factors influencing the performance (i.e. safety and efficacy) of a vaccine against porcine circovirus type 2 (PCV2) in a large number of herds and to estimate customers' satisfaction.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25348652 PMCID: PMC4213548 DOI: 10.1186/s12917-014-0260-1
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Y-Variables screened for feasibility of depicting the ‘outcome’
|
|
|
|
|
|---|---|---|---|
|
| |||
| I_14 | How would you estimate the overall health status of the pig herd | 3.71 | 1.01 |
| I_15.1 | How would you estimate the overall health status of the pig herd | 2.08 | 0.64 |
| I_17.1 | How would you rate the handling of the vaccine? | 1.96 | 0.40 |
| I_18 | How is the following sentence matching your opinion: “My positive expectations of the vaccine’s effect in the pig herd were fulfilled” | 1.95 | 0.65 |
|
| |||
| II_22 | How would you estimate the compatibility of the PCV2 vaccine? | 1.88 | 0.62 |
| II_23 | How would you estimate the overall health status of the pig herd | 3.83 | 1.08 |
| II_24.1 | How would you estimate the overall health status of the pig herd | 2.16 | 0.68 |
| II_27 | How would you estimate the uniformity of growth in the nursery unit | 3.14 | 0.86 |
| II_28 | How would you estimate the uniformity of growth in the nursery unit | 2.22 | 0.47 |
| II_29 | How would you estimate the uniformity of growth in the fattening unit | 3.74 | 0.65 |
| II_30 | How would you estimate the uniformity of growth in the fattening unit | 2.23 | 0.52 |
| II_33.1 | How would you rate the handling of the vaccine? | 2.05 | 0.39 |
| II_34.1 | How would you estimate the efficacy of the vaccine? | 1.97 | 0.73 |
| II_35 | How is the following sentence matching your opinion: ‘My positive expectations of the vaccine’s effect in the pig herd were fulfilled’ | 2.01 | 0.90 |
|
| |||
| D_1415 | [I_15.1]-[I_14] ‘Change in the overall health status due to the use of a PCV2 vaccine’ (veterinarians’ suggestion) | 1.63 | 0.95 |
| D_2324 | [II_24]-[II_23] ‘Change in the overall health status due to the use of a PCV2 vaccine’ (farmers’ suggestion) | 1.65 | 1.06 |
| D_2728 | [II_28]-[II_27] ‘Change in the uniformity of growth in the nursery unit due to the use of a PCV2 vaccine’ (farmers’ suggestion) | 0.92 | 0.92 |
| D_2930 | [II_30]-[II_29] ‘Change in the uniformity of growth in the fattening unit due to the use of a PCV2 vaccine’ (farmers’ suggestion) | 1.51 | 0.83 |
| D_3132 | ‘Change in the estimated mortality rate among fattening pigs due to the use of a PCV2 vaccine (farmers’ suggestion) | NA | NA |
*All ratings were made on a scale ranging from ‘1’ = ‘excellent’ to ‘6’ = ‘unsatisfactory’/NA = not applicable.
Variables, which levels were assessed during telephone interviews with farmers and their veterinarians
|
|
|
|---|---|
|
|
|
| Production type | Clinical observations |
| Herd size | Post mortem inspections |
| Production rhythm | Laboratory examinations |
| Purchase of animals | Time between diagnosis and first vaccination |
| Hygiene measures | |
|
| |
|
| Use of PCV2 vaccines in sows |
| Morbidity | Use of PCV2 vaccines in piglets |
| Mortality | Age of piglets when vaccinated |
| Growth rates | Switch in timing of vaccination |
| Interruption of vaccination against PCV2 | |
|
| Use of antibiotics prior and after vaccination |
| Acclimatisation | Time between vaccination and other measures |
| Vaccination | |
|
| |
|
| Compatibility |
| Age when moving | Perceived efficacy |
| Vaccination | Influence of vaccination on pig health |
| Other treatments | Impact of vaccination on morbidity* |
| Impact of vaccination on mortality* | |
|
| Impact of vaccination on growth rate* |
| Overall satisfaction with the PCV2 vaccine |
*Questions were asked to farmers only.
Independent X-variables assessed via telephone interview with veterinarians and farmers using a PCV2 vaccine in piglets prior to official release to the market
|
|
|
| |
|---|---|---|---|
|
|
| ||
|
| |||
| Production type | Farrow to finish | 47.1 | 107 |
| Farrow to nursery | 26.9 | 61 | |
| Only nursery | 1.3 | 3 | |
| Nursery and fattening | 6.6 | 15 | |
| Only fattening | 18.1 | 41 | |
| Herd size/Sowsa | ≤500 | 78.0 | 131 |
| >500 | 20.8 | 35 | |
| n.a. | 1.2 | 2 | |
| Herd size/Fattening pigs b | ≤500 | 14.7 | 24 |
| 501 - 2,000 | 60.7 | 99 | |
| >2,000 | 21.5 | 35 | |
| n.a. | 3.1 | 5 | |
|
| |||
| Acclimatisation of giltsa | Yes | 61.7 | 103 |
| No | 11.4 | 19 | |
| Own re-breeding | 21.0 | 35 | |
| n.a. | 6.0 | 10 | |
| Farrowing rhythma | 1-week | 42.9 | 72 |
| 2-week | 20.8 | 35 | |
| 3-week | 20.8 | 35 | |
| Other | 15.5 | 26 | |
| Storage of production dataa | Electronic | 89.3 | 150 |
| Hand written | 10.1 | 17 | |
| Nothing | 0.6 | 1 | |
| AIAO in the farrowing unitsa | Yes | 91.1 | 153 |
| No | 8.9 | 15 | |
| Vaccination of sows [S] and gilts [G] againsta | PRRSV [S] | 77.8 | 130 |
| PRRSV [G] | 79.6 | 133 | |
| PCV2 [S] | 13.2 | 22 | |
| PCV2 [G] | 26.4 | 44 | |
| Swine influenza virus | 33.5 | 56 | |
| Porcine Parvovirus & | 98.2 | 164 | |
|
| 4.8 | 8 | |
|
| 24.0 | 40 | |
| Autogenous vaccines | 21.0 | 35 | |
|
| |||
| Age of piglets at weaning (days)a | 21 | 44.1 | 74 |
| 22 – 42 | 54.8 | 92 | |
| n.a. | 1.2 | 2 | |
| Age of piglets when castrateda | ≤7 | 95.8 | 161 |
| 8 – 14 | 4.2 | 7 | |
| Frequency of injecting irona | Once | 67.9 | 114 |
| Twice | 32.1 | 54 | |
| Vaccination of piglets againstc |
| 71.9 | 133 |
| using a 1-shot vaccine | 40.5 | 75 | |
| using a 2-shot vaccine | 19.5 | 36 | |
| n.a. | 18.4 | 34 | |
| PRRSV | 31.4 | 58 | |
|
| 1.6 | 3 | |
|
| 10.3 | 19 | |
| Autogenous vaccines | 1.6 | 3 | |
|
| |||
| AIAO in the fattening unitsb | Yes (by barn) | 8.6 | 14 |
| Yes (by compartment) | 77.9 | 127 | |
| No | 13.5 | 22 | |
| Storage of production datab | Electronic | 16.6 | 27 |
| Hand written | 81.0 | 132 | |
| No | 2.5 | 4 | |
| Disposition of low performing pigs before restockingb | Moving to younger pigs | 9.8 | 16 |
| Euthanasia | 9.2 | 15 | |
| Hospital compartment | 25.8 | 42 | |
| Hospital pen | 33.1 | 54 | |
| Original pen | 9.8 | 16 | |
| Others | 12.3 | 20 | |
|
| |||
| Indication to use the vaccine (farmers’ answer) | Stunted growth | 59.9 | 136 |
| Respiratory diseases | 26.0 | 59 | |
| Enteritis | 4.9 | 11 | |
| PDNS | 44.5 | 101 | |
| Increased mortality | 56.8 | 129 | |
| Marketing | 29.1 | 66 | |
| Other reasons | 33.5 | 72 | |
| Indication to use the vaccine (veterinarians’ answer | Stunted growth | 59.5 | 135 |
| Respiratory diseases | 37.0 | 84 | |
| Enteritis | 15.4 | 35 | |
| PDNS | 45.8 | 104 | |
| Increased mortality | 47.6 | 108 | |
| Marketing | 26.9 | 61 | |
| Other reasons | 26.0 | 59 | |
| Duration of symptoms according to the indication before the vaccine was used for the first time (month) | <3 | 12.3 | 28 |
| 3 – 6 | 4.4 | 10 | |
| >6 | 75.3 | 171 | |
| n.a. | 7.9 | 18 | |
| Diagnostics (other than clinical examination) before vaccination | Yes | 79.7 | 181 |
| No | 20.3 | 46 | |
| Type of diagnostics | Antibody detection by ELISA | 16.3 | 37 |
| of these IgM - IgG ELISA | 1.3 | 3 | |
| PCR | 56.8 | 129 | |
| Necropsy (only gross lesions) | 39.2 | 89 | |
| Histology | 0.0 | 0 | |
| Immuno-histology | 1.3 | 3 | |
| Pathogens other than PCV2 found during these examination | Respiratory pathogens excl. PRRSV | 18.1 | 41 |
| PRRSV or PRRSV & others | 13.7 | 31 | |
|
| 10.6 | 24 | |
|
| 9.7 | 22 | |
| Enteric pathogens excl. | 4.0 | 9 | |
| Others | 0.4 | 1 | |
| None | 43.6 | 99 | |
| Herd health ranking prior to the use of the PCV2 vaccine (farmers’ answer) | 1 (excellent) | 0.0 | 0 |
| 2 | 11.5 | 26 | |
| 3 | 22.5 | 51 | |
| 4 | 33.5 | 76 | |
| 5 | 19.4 | 44 | |
| 6 (unsatisfactory) | 5.3 | 12 | |
| k. A. | 7.9 | 18 | |
| Herd health ranking prior to the use of the PCV2 vaccine (veterinarians’ answer) | 1 (excellent) | 0.0 | 0 |
| 2 | 11.5 | 26 | |
| 3 | 25.1 | 57 | |
| 4 | 35.2 | 80 | |
| 5 | 15.9 | 36 | |
| 6 (unsatisfactory) | 3.1 | 7 | |
| k. A. | 9.3 | 21 | |
| Time between first use of the PCV2 vaccine and the telephone interview (month) | 1 – 6 | 13.2 | 30 |
| 7 – 12 | 73.6 | 167 | |
| 13 – 18 | 11.0 | 25 | |
| n.a. | 2.2 | 5 | |
| Age of piglets when vaccinated against PCV2 (days) | ≤14 | 28.6 | 65 |
| 15 – 21 | 29.1 | 66 | |
| 22 – 28 | 11.5 | 26 | |
| 29 – 69 | 8.8 | 20 | |
| ≥ 70 | 11.9 | 27 | |
| Unknown* | 10.1 | 23 | |
| Stage of production, when pigs are vaccinated against PCV2 | Suckling period | 63.4 | 144 |
| Nursery period | 13.7 | 31 | |
| Fattening period | 12.8 | 29 | |
| Suckling or nursery period* | 10.1 | 23 | |
|
| |||
| Time between PCV2_vaccination and 1st (or 2nd) vaccination against | 0 (in parallel) | 8.7 | 16 |
| 1 – 7 | 7.0 | 13 | |
| 8 – 14 | 4.4 | 10 | |
| ≥15 | 2.7 | 5 | |
| Time between PCV2_vaccination and 1st (or 2nd) vaccination against | 0 (in parallel) | 22.2 | 41 |
| 1 – 7 | 10.8 | 20 | |
| 8 – 14 | 22.7 | 42 | |
| ≥15 | 13.2 | 30 | |
| Time between PCV2_vaccination and PRRSV vaccination (days) c (farmers’ answer) | 0 (in parallel) | 8.7 | 16 |
| 1 – 7 | 0.5 | 1 | |
| 8 – 14 | 1.1 | 2 | |
| ≥15 | 1.1 | 2 | |
| Time between PCV2_vaccination and PRRSV vaccination (days)c (veterinarians’ answer) | 0 (in parallel) | 18.9 | 35 |
| 1 – 7 | 6.5 | 12 | |
| 8 – 14 | 3.2 | 6 | |
| ≥15 | 2.7 | 5 | |
| Substances applied in parallel with the PCV2 vaccine on the other side of the neck | Nothing | 53.3 | 121 |
|
| 24.7 | 56 | |
| PRRSV vaccine | 13.2 | 30 | |
|
| 2.2 | 5 | |
| Others** | 6.6 | 15 | |
| Castration and PCV2 vaccination in parallel | No | 99.6 | 226 |
| Yes | 0.4 | 1 | |
| Interruption of the PCV2 vaccination | No | 92.5 | 210 |
| Yes | 7.5 | 17 | |
| Actual use of the PCV2 vaccine at the time of the interview | No | 10.1 | 23 |
| Yes | 89.9 | 204 | |
| Change in the timing of PCV2 vaccination since started | No | 79.7 | 181 |
| Yes | 14.1 | 32 | |
| n.a. | 0.9 | 2 | |
| Use of other PCV2 vaccines than Ingelvac CircoFLEX® in piglets | No | 87.7 | 199 |
| Porcilis® PCV (MSD) | 6.6 | 15 | |
| Suvaxyn® PCV 2 (Pfizer) | 4.9 | 11 | |
| Circovac® (Merial) | 0.9 | 2 | |
| Reasons for the use of other PCV2 vaccines in piglets | Out of stock | 10.1 | 23 |
| Insufficient efficacy | 0.4 | 1 | |
| n.a. | 1.8 | 4 | |
aonly herds housing sows (n =167).
bonly herds housing fattening pigs (n =163).
conly herds housing suckling and nursery pigs (n =185).
n.a.: not answered.
*pigs were either vaccinated during their suckling period or nursery period; the exact point in time was unknown.
**injection of iron, antimicrobials or other vaccines.
Figure 1Bi-plot showing the results of the principal component analysis of . Black figures represent the dependent variables and blue figures the herds.
Figure 2Bi-plot showing the results of the principal component analysis of . Black figures represent the dependent variables and blue figures the herds.
Figure 3Bi-plot showing the results of a principal component analysis including response clustering for . Black figures represent the dependent variables and green/red figures the herds.
Figure 4Bi-plot showing the results of a principal component analysis including response clustering for . Black figures represent the dependent variables and green/red figures the herds.
p-values of the individual Fisher tests comparing green versus red cluster
|
|
| |
|---|---|---|
|
|
| |
| Reasons for using the vaccine were either wasting, mortality or PDNS, but were not respiratory diseases, enteritis and/or marketing. (veterinarians’ answer) | 0.423 | 0.144 |
| Diagnosis of other diseases than PCVD | 0.071 | 1.000 |
| Acclimatisation of gilts | 0.258 | na |
| Vaccination of sows against PRRSV | 0.395 | na |
| Vaccination of gilts against PRRSV | 0.334 | na |
| Frequency of iron injection in piglets | 0.040 | na |
| Age of piglets when vaccinated against PCV2 | 0.075 | na |
| Reasons for using the vaccine were either wasting, mortality or PDNS, but were not respiratory diseases, enteritis and/or marketing (farmers’ answer) | 0.031 | 0.531 |
| Overall health status of the pig herd prior to the use of the PCV2 vaccine (veterinarians’ answer) | 0.001 | 0.123 |
| Overall health status of the pig herd prior to the use of the PCV2 vaccine (farmers’ answer) | 0.000 | 0.000 |
| Time between first use of the PCV2 vaccine and the telephone interview | na | 0.725 |
| Change in the timing of PCV2 vaccination since started | na | 0.058 |
| Actual use of the PCV2 vaccine at the time of the interview (veterinarians’ answer) | na | 0.343 |
| Actual use of the PCV2 vaccine at the time of the interview (farmers’ answer) | na | 0.285 |
na: not applicable.
Odds ratio estimates and 95% confidence intervals for the ‘GREEN cluster’ in the final model for
|
|
|
|
|---|---|---|
| Only one application of iron in suckling pigs |
| 1.18-6.80 |
| No findings of other diseases than PCVD, when reasons for using the vaccine were respiratory disease, enteritis and/or marketing |
| 0.05-0.56 |
| No findings of other diseases than PCVD, when reasons for using the vaccine were wasting, mortality and/or PDNS, but not respiratory disease, enteritis and/or marketing | 1.32 | 0.35-5.05 |
| Reasons for using the vaccine were neither wasting nor mortality nor PDNS, but were respiratory diseases, enteritis and/or marketing. Simultaneously, no findings of other diseases in the herd |
| 0.02-0.45 |
| Reasons for using the vaccine were neither wasting nor mortality nor PDNS, but were respiratory diseases, enteritis and/or marketing. Simultaneously, findings of other diseases in the herd | 0.84 | 0.29-2.41 |
Numbers in bold font indicate that the odds ratios are significantly different from one at the 5-percent level of significance.
Odds ratio estimates and 95% confidence intervals for the ‘GREEN cluster’ identified in the final model for
|
|
|
|
|---|---|---|
| Time of vaccinating piglets not changed or change to a later point in piglets’ life instead of earlier point in time |
| 1.56-67.9 |
| Time of vaccinating piglets not changed instead of changing to an earlier point in piglets’ life |
| 1.18-21.1 |
| PCV2 vaccine still in use instead of no longer in use | 5.02 | 0.67-37.6 |
Numbers in bold font indicate that the odds ratios are significantly different from one at the 5-percent level of significance.